Fujifilm Gains FDA Approval for its Digital Breast Tomosynthesis Option for Mammography System

January 24, 2017

Stamford, Connecticut–based, Fujifilm Medical Systems U.S.A has achieved FDA approval for its Digital Breast Tomosynthesis (DBT), an optional software upgrade for its Aspire Cristalle digital mammography system.

With the DBT software option, the x-ray tube moves through an arc around the breast, acquiring a series of low-dose image slices at different angles, producing a three-dimensional.

The acquired images are reconstructed into a series of 1 millimeter slices displayed individually or dynamically in a cine mode—making it easier to identify lesions that might be difficult to see in traditional 2D mammography images due to overlapping breast structures. — Cynthia Jessup

View today's stories